Genomic profiling of thyroid cancers has led to the discovery of ALK rearrangements in around 2% of PTCs, including a novel ALK fusion product,STRN-ALK, that is sensitive to available ALK inhibitors (Kelly et al. 2014). The gene discussed is ALK; the disease is thyroid cancer.